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Introduction: Obesity is a known risk factor for breast cancer. Sphingosine kinase 1 (SK1) is an oncogenic lipid
kinase that is overexpressed in breast tumours and linked with poor prognosis, however, its role in obesity-driven
breast cancer was never elucidated.
Methods: Human primary and secondary breast cancer tissues were analysed for SK1 and leptin receptor
expression using quantitative real-time polymerase chain reaction (qRT-PCR) assay. Leptin-induced signalling was
analysed in human oestrogen receptor (ER)-positive and negative breast cancer cells using Western blotting,
qRT-PCR and radiolabelling assays.
Results: Our findings show for the first time that human primary breast tumours and associated lymph node
metastases exhibit a strong correlation between SK1 and leptin receptor expression (Pearson R = 0.78 and R = 0.77,
respectively, P <0.001). Both these genes are elevated in metastases of ER-negative patients and show a significant
increase in patients with higher body mass index (BMI). Leptin induces SK1 expression and activation in ER-negative
breast cancer cell lines MDAMB-231 and BT-549, but not in ER-positive cell lines. Pharmacological inhibition and
gene knockdown showed that leptin-induced SK1 activity and expression are mediated by activation of extracellular
signal-regulated kinases 1/2 (ERK1/2) and Src family kinase (SFK) pathways, but not by the major pathways
downstream of leptin receptor (LEPR) - janus kinase 2 (JAK2) and signal transducer and activator of transcription 3
(STAT3). Src-homology 2 domain-containing phosphatase 2 (SHP2) appeared to be key to SK1 activation, and may
function as an adaptor protein between SFKs and LEPR. Importantly, leptin-induced breast cancer cell proliferation
was abrogated by SK1-specific small interfering RNA (siRNA).
Conclusions: Overall, our findings demonstrate a novel SFK/ERK1/2-mediated pathway that links leptin signalling
and expression of oncogenic enzyme SK1 in breast tumours and suggest the potential significance of this pathway
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Overall 33% of the world’s adult population are over-
weight or obese and, if this trend continues, by 2030 this
figure will be doubled [1]. Obesity is a risk factor for
poor breast cancer prognosis [2] and metastasis [3]; and
oestrogen production and adipokine secretion were
tagged as key elements in this relationship [2-4]. Leptin
is one of the prominent adipokines and its intratumoural
levels are positively correlated with poor breast cancer
prognosis [5], advanced stage [3], metastasis and recur-
rence [6]. The critical role of leptin (rather than just
obesity) in breast cancer progression was highlighted in
an elegant experiment where obese ob/ob mice, which
lack leptin, showed reduced mammary tumour out-
growth compared to increased tumour growth in obese
db/db mice, lacking functional leptin receptor (LEPR)
and hence having high circulating leptin levels [7]. LEPR
is highly expressed in breast tumour tissue and has six
splice variants encoding four isoforms that share an
identical intracellular domain Box1 that is critical for
Janus kinase (JAK) binding and activation. The longest
isoform of LEPR (LEPR-Long) also contains a binding
site for signal transducer and activator of transcription
(STAT) [8]. Leptin signalling triggers activation of extra-
cellular signal-regulated kinases 1/2 (ERK1/2), STAT3,
and phosphatidylinositol 3-kinase (PI3K)/Akt [9]. Inter-
estingly, leptin retains the ability to stimulate STAT3
and ERK1/2 in cells lacking JAK2 kinase, where JAK2-
independent responses appear to be mediated by mem-
bers of the src family kinases (SFKs) [10].
Leptin promotes cellular proliferation in both oestrogen
receptor (ER)-positive and -negative breast cancer cell
lines [11]. In breast cancer leptin is also a positive regula-
tor of vascular endothelial growth factor (VEGF) and
blockade of leptin signalling markedly reduces VEGF
expression and the tumour growth in mouse xeno-
grafts [12].
Sphingosine kinase 1 (SK1) is an oncogenic enzyme
that is highly expressed in human tumours and has been
shown to act as a ‘signalling hub’ mediating cancer pro-
gression, angiogenesis and cell migration, making it a
key molecule in the search for potential anticancer
therapies [13]. High levels of SK1 expression have been
shown in various human tumour tissues (including
breast) [14], where they enhance angiogenesis and are
associated with chemoresistance and a poor prognosis
[15]. SK1 mRNA expression increases through the four
stages of breast cancer [16], is higher in ER-negative
tumours and is associated with disease progression and
poor prognosis [17], however, the mechanism of its up-
regulation is not determined.
The metabolic profile of fat tissue from obese subjects
(compared with lean subjects) exhibits a high content of
sphingosine-1-phosphate (S1P, a product of SK1 activity),which promotes proliferative responses, suggesting that
obesity may be a factor affecting SK1 levels [18]. Until
now no direct links between leptin-mediated signalling
and SK1 in breast cancer have been documented.
Our data show for the first time a strong correlation
between SK1 and LEPR expression in human primary
breast tumours and associated lymph node metastases.
The levels of both genes were significantly increased in
patients with higher body mass index (BMI) and in the
lymph node metastases of ER-negative patients. In ER-
negative breast cancer cells leptin induces SK1 expres-
sion and activation through ERK1/2 and src-homology 2
domain-containing phosphatase 2 (SHP2)/SFKs pathways
and independently of JAK2/STAT3. Consequently, SK1
activation is critical for leptin-induced breast cancer cell
proliferation. Our findings demonstrate a novel pathway
that links leptin signalling and expression of oncogenic
enzyme SK1 in breast tumours, which may have a physio-




Archival paraffin-embedded tissue from 69 patients with
primary breast tumours and corresponding lymph node
(LN) metastases was obtained from Imperial College
NHS Trust tissue bank. Prior to donating their samples
to the bank, all patients consented for their subsequent
use in research projects and publications. The study was
approved by National Research Ethics Service and per-
formed in accordance with ethical guidelines. None of
the patients received neo-adjuvant therapy. Clinicopath-
ological details of the patients enrolled in this study are
listed in Table S1 in Additional file 1. All samples were
formalin-fixed and paraffin-embedded (FFPE). Four sec-
tions (5 μm thick) were macrodissected from the FFPE
blocks with trimming of excess paraffin. Only tissue con-
taining at least 70% of tumour was used for RNA
isolation.
Chemicals and antibodies
Recombinant human leptin was obtained from Sigma-
Aldrich (St. Louis, MO, USA). [γ-32P]-ATP (6,000 mCi/
mmol) was purchased from PerkinElmer (Waltham,
MA, USA), silica gel G60 plates from GE Healthcare
(Waukesha, WI, USA) and sphingosine from Avanti
Polar Lipids (Alabaster, AL, USA). Wortmannin, LY294002,
and SU6656 were from Calbiochem (Darmstadt, Germany),
UO126 was from New England Biolabs (Hitchin, UK).
Antibodies for p-SFK (Tyr416), total Src (cross-reacts with
other SFK family members), ERK 1/2, phospho (p)-STAT 3,
p-Akt (Ser473), Akt, JAK2 were obtained from New
England Biolabs (Hitchin, UK). p-ERK 1/2 from Sigma-
Aldrich (Steinhelm, Germany), STAT-3 from Santa Cruz
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and chemicals used were purchased from Sigma-Aldrich
(Gillingham, UK) unless otherwise specified.
Cell culture
Breast cancer cell lines MDAMB-231, BT-549, MCF7
and BT-474 were purchased from ATCC (Manassas, VA,
USA). All cells were maintained in tissue culture flasks
or plastic dishes in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% heat-inactivated foetal calf serum
(FCS) (FirstLink, Birmingham, UK), 50 U/ml penicillin,
50 μg/ml streptomycin and 2 mM glutamine (Sigma-Al-
drich, St. Louis, MO, USA) in a humidified atmosphere
of 5% CO2 at 37°C. Cell lines were kept in culture for up
to 30 passages.
Cell treatment and preparation of cell lysates
Cells were seeded to reach 70 to 80% confluence by the
end of the treatment. Next day, cells were washed with
serum-free media and starved overnight. Leptin and
pharmacological inhibitors (1 h prior to leptin) were
added at the concentrations and for the times indicated
in the figure legends. After incubation cells were washed
with ice-cold phosphate-buffered saline (PBS) and then
harvested.
RNA extraction and cDNA synthesis and qRT-PCR
Samples were dissolved in RLT lysis buffer and isolation
of total RNA was performed using the RNeasy Mini kit
(Qiagen, Valencia, CA, USA) as per manufacturer’s in-
structions. RNA quantity and purity was measured using
a NanoDrop ND-100 Spectrophotometer (Thermo
Fisher Scientific, Loughborough, UK). Reverse transcrip-
tion was performed using Precision nanoScript™ Reverse
transcription kit (PrimerDesign Ltd, Southampton, UK).
qRT-PCR was done using Precision™ 2X qPCR Master-
mix with SYBR green™ and 6-carboxyl-X-rhodamine
(ROX) as a reference dye (PrimerDesign Ltd, Southamp-
ton, UK) as per manufacturer's instructions. For meas-
urement of breast cancer clinical samples, double-dye
(Taqman™) primers (Table S2 in Additional file 1) were
used with PrimerDesign 2X Precision™ MasterMix con-
taining ROX using ABI PRISM 7900 sequence detection
system (Applied Biosystems, Darmstadt, Germany). Ct
values were exported and analysed using qbase software
(Biogazelle NV, Zwijnaarde, Belgium) using multiple ref-
erence genes normalisation. The expression of SYBR
green target genes (SK1, VEGF and SHP2) was normal-
ised to three reference genes: ubiquitin C (UBC), glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH), and
tyrosine-3-monooxy-genase/tryptophan 5-mono-oxygen-
ase activation protein (YWAZH). Breast cancer clinical
samples were normalised to five housekeeping genes:
GAPDH, beta glucuronidase (GUSB), TATA box bindingprotein (TBP), eukaryotic 18S rRNA (18S) and mito-
chondrial ribosomal protein L19 (MRPL19).
Proliferation assay
Cells were seeded in 96-well plates and incubated for
24 h, then starved for 24 h and then incubated with or
without leptin and/or SK1 small interfering RNA (siRNA).
MTT assay - 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) was added to each
well. After 3.5 h of incubation at 37°C, supernatant was
aspirated and formazan crystals were dissolved in 0.5 M
dimethylformamide and 20% SDS. Optical density was
read at 570 nm using a microplate reader (Tecan Sunrise™,
Mannedorf, Switzerland).
Western blotting
Western blot analysis was performed as previously
described [19,20]. Cell pellets were dissolved in 1X SDS
loading dye and protein quantification was carried out
by Dc protein assay (Bio-Rad Laboratories, Hercules,
CA, USA). Proteins (20 to 30 μg) were loaded on acryl-
amide mini gels and run at 110 V. Separated proteins
were transferred onto PVDF Immobilon-P™ membranes
then blocked in PBS-T containing 5% (w/v) non-fat dry
milk for 1 h at room temperature. Primary antibodies
were diluted in 5% bovine serum albumin (BSA)/PBS-T
containing sodium azide and incubated overnight at
4°C. Secondary peroxidase-conjugated antibodies against
mouse or rabbit IgG (GE Healthcare, Amersham, UK)
were added in PBS-T/milk. Membranes were exposed to
chemiluminescent horseradish peroxidase (HRP) substrate
(GE Healthcare (Amersham, UK)) and visualised using
X-ray films (SLS, Hessle, UK) on an SRX-101A X-ray
developer.
Sphingosine kinase 1 assay
SK1 assay was performed using radiolabelling as previ-
ously described [21]. Cell lysates were resuspended in
SK1 buffer (20 mM Tris-HCl pH7.4, 20% glycerol, 1 mM
2-mercaptoethanol, 1 mM EDTA, 10 μg/ml PMSF, 15 mM
NaF, 10 μg/ml leupeptin, aprotinine, Soybean trypsin
inhibitor, 0.5 mM 4-deoxypyridoxine, 40 mM B-glyc-
erophosphate, 1 mM sodium orthovanadate). Lysates
were sonicated and centrifuged at 20,000 g for 30 min at
4°C. Protein concentration in the supernatant was esti-
mated by Bradford protein assay (Bio-Rad, Munich,
Germany). Each sample was resuspended in 200 μl SK1
buffer and 50 mM sphingosine, 20 mM MgCl2, 20 mM
ATP and 10 μCi [γ-32P]-ATP (6000 Ci/mmol) were added
and incubated for 1 h at 37°C. The reaction was stopped
by addition of 50 μl 1 M HCl, 800 μl chloroform/metha-
nol/HCl, 240 μl chloroform and 240 μl 2 M KCL. After
centrifugation, the lower organic phase was collected
and vaporised. Dried lipids were solubilised with 40 μl
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chromatography on silica gel G60 plates using 1-butanol/
ethanol/acetic acid/water (80:20:10:20, v/v) as migration
solution. Plates were air-dried, exposed to X-ray film and
quantified using Image J software.
RNA interference
Cells were seeded at a density to reach 30 to 50% conflu-
ence by the day of transfection. Forty nm siRNA oligonu-
cleotides combined with oligofectamine in Opti-MEM™
(Invitrogen, Carlsbad, CA, USA) were used. siRNA direc-
ted against SK1 was obtained from Applied Biosystems.
All other siRNAs were purchased from Thermo Fisher
Scientific (Loughborough, UK) as pooled four independ-
ent sequences. Non-targeting siRNA, were used as a nega-
tive control (Table S3 in Additional file 1). Optimal
knockdown was obtained 72 h post-transfection and veri-
fied by western blot or qRT-PCR.
Statistical analysis
Data are presented as the mean values normalised to
control ± standard error of the mean (SEM) calculated
using GraphPad Prism (GraphPad Software, La Jolla,
CA, USA). Statistical significance between two groups
was conducted by unpaired Student’s t test. Compari-
sons between the means of more than two groups were
assessed using one-way ANOVA analysis followed by a
Tukey’s test (95% confidence). The Pearson’s correlation
coefficient was calculated between the expression levels
of two target genes. Multivariate analysis was performed
to find the parameters fitting the best linear regression
model based on the minimization of Akaike information
criterion. The odds ratio (OR) for all pairs of parameters
has been calculated via logistic regression.
Results
Expression of LEPR-Long and SK1 correlates in human
breast tumours and metastatic lymph nodes, and is
elevated in patients with high BMI
We have used Taqman qRT-PCR to quantify LEPR-Long
and SK1 expression in macrodissected paraffinised sec-
tions of breast tumours and corresponding LN metastases
obtained from 69 patients. There was a strong positive
correlation between LEPR-Long and SK1 both in tu-
mours (P <0.001, R = 0.78) and LNs (P <0.001, R = 0.77)
(Figure 1A,B). Both LEPR-Long and SK1 expression in
primary tumours correlated with their relative expression
in corresponding metastatic LNs (Figure 1C,D). Import-
antly, patients with higher BMI had higher levels of LEPR-
Long and SK1 in tumours (P <0.05) and LNs (not signifi-
cant) (Figure 1E). Furthermore, in ER-negative patients,
SK1 and LEPR-Long expression was significantly higher in
metastatic LNs than in primary tumours or LNs from
ER-positive patients (Figure 1F). A similar trend wasnoticed, albeit to a lower extent, in triple-negative tu-
mours when compared to triple-positive (Figure S1A in
Additional file 2). Analysis of LEPR-Long and SK1 expres-
sion with respect to progesterone receptor (PR), and hu-
man epidermal growth factor receptor (HER) expression
and menopausal status in tumours and LNs showed no
significant differences (Figure S1B-D in Additional file 2).
Multivariate linear regression model for outcomes (LN
LEPR-Tumour LEPR) and (LN SK1-Tumour SK1) based
on the minimization of Akaike information criterion
showed that combination of ER status and tumour size
had the best correlation to the LEPR and SK1 expression
(Table S4 in Additional file 1). To estimate the pairwise
influence of parameters, we have split them by tertiles and
calculated odds ratios (ORs) with respect to the first group
via a logistic regression (Tables S5,S6 in Additional file 1).
The combination of tumour grade and HER2 status
showed the most significant ORs of (9.8 and 4.1) to have
LEPR expression higher in lymph nodes than in tumours
(Table S5 in Additional file 1). Table S6 in Additional file 1
shows that the risk for high SK1 expression is elevated in
ER-negative (OR = 9.9), or obese (OR = 9.625) patients, or
both (OR = 6.111).Leptin induces breast cancer cell proliferation
Assessment of cellular proliferation by MTT assay showed
that MDAMB-231 cells treated with 10, 100 and 1,000 ng/
ml leptin exhibited a significant increase in proliferation
from 72 to 120 h, with the maximum effect obtained at
1,000 ng/ml (Figure 2A). Importantly, specific knockdown
of SK1 has abolished these proliferative responses in both
MDAMB-231 and BT-549 cells (Figure 2B; Figure S2 in
Additional file 2).Analysis of leptin-induced pathways in ER-negative and
-positive breast cancer cell lines
Dose-dependent treatment of MDAMB-231 cells with
leptin showed that 1,000 ng/ml led to a maximal STAT3
phosphorylation at 1 h and 6 h, and to a lesser extent at
10 min. This was paralleled by a marked increase in
SFKs phosphorylation (P <0.001) (Figure 3A; Figure S3 n
Additional file 2). Importantly, 1,000 ng/ml leptin indu-
ced a 30 to 60% increase in SK1 mRNA expression at 1
to 6 h, which was mirrored by VEGF (Figure 3B,C).
Similarly to mRNA expression, 1,000 ng/ml leptin trig-
gered a 46% increase in SK1 activity after 1 h of treatment
(P <0.01) followed by a second peak at 6 h (26% increase,
P <0.05) (Figure 3D). Another ER-negative breast cancer
cell line BT-549 showed a similar response (Figure S4,S5
in Additional file 2). In ER-positive MCF-7 and BT-474
cells leptin induced a marked increase in STAT3 phos-
phorylation, but failed to induce SFK activation or SK1
and VEGF expression (Figure S6-S8 in Additional file 2),
Figure 1 (See legend on next page.)
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Figure 1 SK1 expression correlates with LEPR-Long expression in tumours and positive lymph nodes from breast cancer patients with
higher expression of those genes oestrogen receptor-negative breast lymph-node metastases and in the tumours of obese and
overweight patients. RNA was extracted from human breast cancer samples and expression of SK1 and LEPR-Long mRNAs was determined by
qRT-PCR, (normalised against GAPDH, GUSB, TBP, 18S and MRPL19) and analysed using qBase software. Correlation between SK1 and LEPR-Long
expression in primary tumours (A) and metastatic LNs (B). Correlation between LEPR-Long (C) and SK1 (D) expression in primary tumours and
metastatic LN. (E) Expression of LEPR-Long and SK1 with respect to BMI (<24.9 or >25) in primary tumours and metastatic LN. (F) Expression of
LEPR-Long and SK1 in primary tumours and metastatic LNs of ER-positive and -negative breast cancer patients. Pearson correlation coefficient (R),
square Pearson correlation coefficient (R2) and statistical significance (P) are indicated. Columns, represent the mean; bars, SEM. (*, P <0.05; **,
P <0.01; §, P <0.001; NS, not significant, P >0.05). ER, oestrogen receptor; LNs, lymph nodes.
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cells.
JAK2/STAT3 and PI3K/Akt pathways regulate
leptin-induced expression of VEGF, but not of SK1
Binding of leptin to its receptor LEPR-Long autophos-
phorylates JAK2, which in turn activates the tyrosine
residue leading to STAT3 phosphorylation [9]. Of note,
STAT3 phosphorylation was only modestly decreasedFigure 2 Leptin does not increase the proliferation of MDAMB-231 ce
starved overnight then incubated with 10 to 1,000 ng/ml leptin for 5 days.
were transfected with specific siRNA against SK1 (siSK1) or control siRNA (s
1,000 ng/ml leptin for 5 days. Cell proliferation was followed using MTT ass
sextuplicate; bars, SEM. (*, P <0.05; **, P <0.01; §, P <0.001; NS, not significanupon JAK2 silencing (Figure 4A; Figure S9A in Additional
file 2). Likewise, silencing of JAK2 or STAT3 had no
effect on leptin-induced SK1 expression (Figure 4B),
while leptin-induced VEGF expression was abolished
(Figure 4C). Surprisingly, knockdown of STAT3 dramatic-
ally upregulated SK1 expression (P <0.001) in MDAMB-
231 (Figure 4B) and BT-549 cells (Figure S10 in
Additional file 2). To exclude an ‘off-target’ effect of
STAT3 siRNAs, cells were transfected with each of thells in the absence of SK1 signalling. (A) MDAMB-231 cells were
Cell proliferation was followed using MTT assay. (B) MDAMB-231 cells
iCont). Cells then were starved overnight then incubated with
ay. Columns, mean of three independent experiments performed in
t, P >0.05).
Figure 3 (See legend on next page.)
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Figure 3 Leptin activates p-STAT3 and P-SFK, increases SK1 expression and enzymatic activity and VEGF expression in MDAMB-231
cells. Cells were starved overnight in serum-free media then exposed to 10 to 1,000 ng/ml of leptin for indicated times. (A) Cell lysates obtained
after each time point were separated on a 10% SDS-PAGE gel and probed for phosphorylation of STAT3, Akt, SFK and ERK1/2. Blots are representative
of three independent experiments. Expression of SK1 (B) and VEGF (C) determined by qRT-PCR, normalised against housekeeping genes (GAPDH,
YWHAZ and UBC) and analysed using qBase software. (D) SK1 activity was measured by radiolabelling of sphingosine in cell lysates containing equal
amounts of protein. Columns, mean of three independent experiments; bars, SEM. (*, P <0.05; **, P <0.01; §, P <0.001; NS, not significant, P >0.05).
Figure 4 JAK2 silencing or PI3K/Akt inhibition does not abrogate SK1 expression. (A-C) MDAMB-231 cells were transfected with specific
siRNA against STAT3 (siSTAT3) and JAK2 (siJAK2) or control siRNA (siCont). Cells were starved overnight in serum-free media then exposed to
1,000 ng/ml leptin for 6 h. (D-F) MDAMB-231 cells were starved overnight in serum-free media then pre-treated with PI3K/Akt inhibitors wortmannin
(1 μM) and LY294002 (10 μM) for 1 h followed by stimulation with 1,000 ng/ml leptin for 6 h. (A, D) Cell lysates obtained were separated on a 10%
SDS-PAGE gel and probed for phosphorylation of STAT3, JAK2 and ERK1/2 to verify knockdown efficiency or Akt to confirm that the inhibitor worked
under the experimental conditions. Expression of SK1 (B, E) and VEGF (C, F) determined by qRT-PCR, normalised against housekeeping genes (GAPDH,
YWHAZ and UBC) and analysed using qBase software. Columns, mean of three independent experiments performed in triplicate; bars, SEM. (*, P <0.05;
**, P <0.01; §, P <0.001; NS, not significant, P >0.05) when comparing levels of SK1, and VEGF mRNA to siCont levels.
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silenced STAT3 and consistently induced SK1 expression,
while the fourth oligonucleotide was less effective in both
(Figure S11 in Additional file 2). As assessed by Akt
phosphorylation, the PI3K/Akt inhibitors were effective at
inhibiting their respective signalling pathways, without
off-target on ERK1/2 pathway (Figure 4D-F). PI3K/Akt
inhibitors wortmannin (1 μM) and LY294002 (10 μM)
slightly attenuated STAT3 phosphorylation and decreased
leptin-induced VEGF expression, but not SK1 expression.
LY294002 has also significantly decreased the basal ex-
pression of VEGF and SK1, which could not be noticed
with wortmannin (LY294002 is known bind to other tar-
gets unrelated to the PI3K family [22]).
SK1 and VEGF expression is regulated by MAPK and SFKs
pathways
Revealing a nonessential role of JAK2 in leptin-mediated
SK1 activation prompted us to identify JAK2-independent
pathways. The pharmacological inhibitors were successful
at inhibiting their respective targets, as assessed by the
phosphorylation status of ERK and SFKs. Inhibition of
MEK1/2 by UO126 and SFKs by SU6656 strongly
suppressed SK1 and VEGF expression and SK1 activity
(Figure 5). The combination of UO126 and SU6656 acted
similarly to the stronger of the two inhibitors. While
UO126 predominantly affected SK1 expression, SU6656
was most effective in inhibiting SK1 activity indicating
differential, non-additive mechanisms by which these
pathways affect SK1. While both inhibitors lowered basal
VEGF expression, in contract to SU6656, UO126 did not
inhibit leptin-induced VEGF expression. Interestingly,
inhibition of ERK1/2 decreased SFKs phosphorylation,
but markedly increased STAT3 phosphorylation (appro-
ximately 2.5-fold, P <0.001). In contrast, SFKs inhibition
significantly decreased STAT3 phosphorylation, which is
also noticed to a lesser extent in combination with UO126
(P <0.001) (Figure 5; Figure S12 in Additional file 2).
Pharmacological inhibition of ERK1/2 and SFKs was veri-
fied using specific siRNA pools against ERK1/2, Src and
Fyn (Figure S13-S15 in Additional file 2). Similar data was
obtained in BT-549 cells, where inhibition of ERK1/2 and/
or SFKs inhibited both basal and leptin-induced SK1 and
VEGF expression (Figure S16 in Additional file 2).
Knockdown of SHP2 decreases SFKs phosphorylation and
SK1 expression
SHP2 was shown to activate SFKs, independently of its
enzymatic activation, by binding to their SH3 domain
[23]. Since we were interested in the pathways down-
stream of SHP2 which might be affected with its knock-
down, the phosphorylation status of the different forms
of SFKs and ERK1/2 were assessed (Figure 6). The inhib-
ition of SHP2 expression did not lead to any change inp-SFK Tyr 527 or np-SFK Tyr 527, but reduced leptin-
induced p-SFK Tyr 416 and SK1 expression by 40% and
30% respectively (Figure 6; Figure S17 in Additional file 2).
Unlike Src inhibitors, SHP2 knockdown did not alter basal
and leptin-mediated VEGF expression or STAT3 phos-
phorylation (Figure 6). Similar findings were obtained in
BT-549 cells (Figure.S18 in Additional file 2).
Discussion
Tumour microenvironment is now recognised as a new
key player in cancer progression. Breast is mainly com-
posed of adipose tissue and many studies have shown a
positive association between obesity and breast cancer.
Several mechanisms have been proposed to explain this
link, including high levels of the adipokine leptin. Bind-
ing of leptin to its receptor LEPR-Long elicits a prolifer-
ative and angiogenic signal transduction cascade, which
varies remarkably depending on cancer cell types. Simi-
larly to leptin, an oncogenic lipid kinase SK1 was shown
to be overexpressed in human breast tumours and linked
with poor prognosis, yet the mechanism of its upregula-
tion in breast cancer was not clear.
Using human clinical samples, we show for the first
time that there is a strong positive correlation between
LEPR-long and SK1 both in human breast tumours and
metastatic LNs (Figure 1). Expression of both genes cor-
relates between tumours and relative LNs, indicating the
persistence of this pathway during cancer metastasis. A
number of studies support the association between high
LEPR/leptin expression and breast cancer progression
[5,6,24], metastasis [6] and ER-negativity [24]. We show
that increased expression of both LEPR and SK1 specif-
ically correlates with metastasis in ER-negative patients
and several mechanisms of SK1-driven metastasis have
been suggested in other systems [25,26]. Our data confirm
previous findings showing that SK1 mRNA is expressed in
both ER-positive and negative breast cancer and is in-
creased in ER-negative tumours [17]. Both genes are
strongly associated with higher BMI, which is supported
by the data showing that both obesity [18] and breast
cancer metastasis [27] have been correlated with higher
serum levels of the SK1 product S1P. Our data is rein-
forced by a study showing a polymorphism at codon 109
in the leptin receptor gene, which occurs more frequently
in patients who are overweight [28]. Interestingly, these
patients had higher plasma leptin levels, particularly the
ones with ER-negative tumour phenotype.
Importantly, we show that SK1 plays a key role in
leptin-induced breast cancer cell proliferation (Figure 2),
indicating a clear physiological importance of this path-
way. Overexpression of SK1 in breast cancer cells was
shown to promote cell growth [29], and our data show for
the first time its regulation by LEPR, which functionally
links obesity and breast cancer. Our data corroborates the
Figure 5 Inhibition of ERK1/2 and SFK attenuates SK1 expression and enzymatic activity and VEGF expression. MDAMB-231 cells were
starved overnight in serum-free media and pre-treated with MEK1/2 inhibitor U0126 (10 μM) and/or SFK inhibitor SU6656 (10 μM) for 1 h followed
by stimulation with 1000 ng/ml leptin for 6 h. (A) Cell lysates were separated on 10% SDS-PAGE gel and probed for phosphorylation of STAT3,
SFK and ERK1/2. Blots are representative of three independent experiments. SK1 (B) and VEGF (D) expression and SK1 activity (C) were measured
in cell lysates containing equal amounts of mRNA and protein. SK1 activity was measured by radiolabelling of sphingosine. For qRT-PCR, SK1 and
VEGF were normalised against housekeeping genes (GAPDH, YWHAZ and UBC) and analysed using qBase software. Columns, mean of three
independent experiments performed in triplicate; bars, SEM. (*, P <0.05; **, P <0.01; §, P <0.001; NS, not significant, P >0.05).
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http://breast-cancer-research.com/content/16/4/426recent finding that leptin receptor expression is required
to maintain cancer stem-like properties in triple-negative
breast cancer cells [30]. While it was not possible to fully
differentiate the effects of SK1 knockdown on leptin sig-
nalling versus its effect on other pro-survival signalling
pathways, our data give an indication that SK1 knock-
down is effective counterbalancing the effects of leptin,
reducing leptin-induced cell proliferation on 39% (average
72 to 120 h) vs 27% in control cells.
The mechanism of enhanced SK1 expression in ER-
negative breast cancer was never elucidated. Our in vitro
findings show a new pathway of leptin-mediated SK1
expression in ER-negative breast cancer cells where lep-
tin induces phosphorylation of STAT3 and SFK and an
increase in SK1 mRNA expression and activity (Figure 3;
Figure S4-S5 in Additional file 2). Surprisingly, in ER-
positive cells leptin fails to induce SFK activation or SK1
and VEGF expression despite a marked increase in STAT3
phosphorylation (Figure S6-S8 in Additional file 2), indi-
cating the prevalence of this pathway in ER-negative cells.
Indeed, MDAMB-231 cells form more aggressive tumoursthan MCF-7 cells [31] and secrete higher levels of
leptin and VEGF [12]. The differential activation of
leptin-mediated signalling pathways across different
breast cancer cell lines may further account for the
distinctive activation profile of SK1. In contrast, to leptin
signalling, the clear role of SK1 in response to ER-α was
described previously in detail [32]. Therefore, further stud-
ies are required to investigate the differential response of
SK1 to leptin depending on ER expression profiles.
SFKs play an important role in breast cancer oncogen-
esis. Importantly, to our knowledge, leptin-mediated
activation of SFKs has not been previously reported in
breast cancer and here we provide the first evidence of
leptin-mediated SFKs phosphorylation at Tyr 416 in ER-
negative breast cancer cell lines (Figure 3). Previous
studies in other cell systems indicate that SFKs can induce
VEGF expression [33], and increase SK1 expression and
enzymatic activity [34]. Importantly, recent evidence sug-
gests that in breast cancer high nuclear localisation of
SK1, combined with high levels of cytoplasmic p-SFK (Tyr
416) or Lyn shortens disease recurrence time [35].
Figure 6 Knockdown of SHP2 decreases SFK phosphorylation and SK1 expression. MDAMB-231 cells were transfected with specific siRNA
against SHP2 (siSHP2) or control siRNA (siCont). Then cells were starved overnight in serum-free media followed by stimulation with 1,000 ng/ml
leptin for 6 h. (A) Cell lysates obtained were separated on a 10% SDS-PAGE gel and probed for phosphorylation of STAT3, SFK and ERK1/2.
(B) Expression of SHP2 determined by qRT-PCR to verify knockdown efficiency. Expression of SK1 (C) and VEGF (D) mRNA determined by qRT-PCR,
normalised against housekeeping genes (GAPDH, YWHAZ and UBC) and analysed using qBase software. Columns, mean of three independent
experiments performed in triplicate; bars, SEM. (*, P <0.05; **, P <0.01; §, P <0.001; NS, not significant, P >0.05).
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http://breast-cancer-research.com/content/16/4/426However, it is not clear what caused the high level of SFK
phosphorylation observed in the absence of leptin at 1
and 24 h (Figure 3A). Taken into consideration the pattern
of activation observed with regards to time and the treat-
ment, it is possible that the initial SFK phosphorylation in-
duced by leptin at 10 min and 6 h was followed by a
desensitization phase, which has led to relative higher
levels in control in comparison with leptin-stimulated
cells. The activation at 24 h could be also explained by a
general desensitisation to the signal as leptin signallingwears off and as metastatic cancer cells produce their own
growth/proliferation factors.
Unexpectedly, JAK2 silencing did not alter leptin-
induced STAT3 phosphorylation, and SK1 expression,
while, similarly to a previous report [36], knockdown of
either JAK2 or STAT3 abolished leptin-induced VEGF
expression (Figure 4; Figure S9-S11 in Additional file 2).
This suggests the presence of two distinct leptin-
driven pathways [10] that regulate the expression of
these genes in ER-negative breast cancer cells. Indeed,
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http://breast-cancer-research.com/content/16/4/426here we provide the first evidence that in ER-negative
breast cancer cell lines ERK1/2 and SFKs pathways regu-
late leptin-mediated increase in SK1 expression and activ-
ity (Figures 5, 7, Figure S12-S16 in Additional file 2), while
JAK2/STAT3, PI3K/Akt, ERK1/2 and SFKs pathways
regulate expression of VEGF (Figures 4, 5, 7).
Differential inhibition of SK1 activity and expression
by UO126 and SU6656 shows that SFKs mainly affect
the enzyme activity whereas ERK1/2 affect mostly its
basal transcriptional levels. Our data are consistent with
a previous report showing that UO126 decreases PMA-
induced SK1 expression [37]. Concurrent inhibition of
ERK1/2 and SFKs signalling did not provide any synergis-
tic or additive effect, but displayed a phenotype consistent
with the stronger inhibitor; UO126. It is therefore highly
probable that these molecules are involved in separate
signalling pathways; nonetheless, they coordinate leptin
responses through a similar downstream mechanism
involving SK1.
An unexpected observation is the reduction of SFK
phosphorylation after treatment with UO126. A similar
reduction has been shown in response to UO126 in rat
intestinal epithelial cells [38] and a similar reduction in
p-SFK was observed when using siERK1/2 (Figure S13 in
Additional file 2), ruling out the non-specific inhibitor
effects. ERK1/2 was reported to inhibit the ubiquitination
pathway [39], which is known to contribute to p-SFKs
degradation in the absence of downstream signalling
[40,41]. In all of our experiments, the total SFK levels
remained unchanged and it was only p-SFK that was
downregulated. We therefore conclude that it is possibleFigure 7 Overall mechanism of leptin-mediated activation of downstr
SFKs-mediated mechanisms. ERK1/2 inhibits STAT3 activation, and STAT3 in
JAK2/STAT3, PI3K/Akt, SFKs and ERK1/2-mediated mechanisms.that: (a) inhibition of ERK may lead to activation of the
ubuiqitination pathway and subsequent degradation of
p-SFK or (b) there is an unknown feedback mechan-
ism linking ERK1/2 and SFK phosphorylation.
One interesting finding is that MEK1/2 inhibition or
knockdown increases STAT3 phosphorylation (Figure 5;
Figure S13, S16 in Additional file 2). It was shown that
mutation in the LEPR site responsible for ERK activation
leads to enhanced STAT3 signalling [42], while expression
of constitutively active MEK inhibits STAT3 activation
[43]. These data suggest that ERKs and STAT3 form a
negative feedback loop, limiting the intensity of STAT3
activation [43].
SHP2 has an oncogenic role in triple-negative breast
cancer [44], and functions as an adaptor protein in LEPR
signalling to ERK1/2 [42]. SHP2 was also shown to induce
Src activation through enzymatic [45] and non-enzymatic
mechanisms [23]. Our data show for the first time that
SHP2 knockdown reduces p-SFK Tyr 416, but not Tyr
527 in leptin-treated MDA-MB-231 and BT-549 cells and
is critical for leptin-induced SK1 expression (Figure 6;
Figure S17, S18 in Additional file 2).
Breast cancer clinical phenotype is a key factor in
designing therapeutic approaches. In ER-positive tumours
SK1 expression was reported to have no detrimental effect
[46], on the contrary, high SK1 expression in ER-negative
tumours is associated with shorter disease-specific survival
[17,47]. Therefore, SK1 inhibitors might be of little use for
the treatment of ER-positive breast cancer [48], while our
data indicate that they may have some potential in treat-
ment of ER-negative tumours, specifically in the contexteam signalling. (A) Leptin activates SK1 through ERK1/2 and SHP2/
hibits SK1 expression. (B) Activation of VEGF expression occurs via
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http://breast-cancer-research.com/content/16/4/426of high BMI. In other cancer systems we have previously
demonstrated a significant potential for the SK1-targeting
therapies, specifically in combination with docetaxel che-
motherapy [19,49-51]. In triple-negative breast cancer
models inhibition of SK1 decreases cell proliferation [52]
and reduces primary tumour size and LN metastasis [27].
Conclusions
Our study identifies SK1 as a new player in leptin-
induced response in ER-negative breast cancer cells and
tissues. Contrary to well-studied leptin-induced VEGF
expression, the findings in this study provide a novel
SHP2/SFKs- and ERK1/2-dependent mechanism of lep-
tin-mediated SK1 regulation. Recent clinical data links
obesity with ER- and PR-negative tumours and poor
overall survival in patients with breast cancer [53]. A
recent WINS trial demonstrated that low-fat diet and
corresponding weight loss showed a relapse-free sur-
vival benefit only in ER-negative breast cancer patients
[54]. While this effect is clearly multifactorial and may
be linked to changes in sex hormone levels, insulin, adi-
pokines and inflammatory response, leptin reduction
may play a role in the achieved outcome and our data
show a new mechanism of leptin-mediated effect on
breast cancer signalling (Figure 7). The findings in this
work point to the possibility of targeting SK1 in ER-
negative tumours and obese individuals to deter breast
cancer progression. Further investigation is required
to delineate the exact mechanism of SK1 expression
as well as its subsequent influence on breast tumour
progression.
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